Clavulanic Acid

CHEMBL777 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

199.2 g/mol

LogP

-1.2

Phase

4

A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.

Peso Molecular

199,1600 g/mol

LogP

-1,20

TPSA

87,10 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Bladder Cancer Pain Management Asthma Chronic Obstructive Pulmonary Disease Generalized Anxiety Disorder Infectious Disease Chronic Kidney Disease Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Chronic Pain Tuberculosis Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Mecanismo de Ação

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21

InChI

InChI=1S/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1

Molecular Formula

C8H9NO5

HBD / HBA

2 / 5

Ligações Rotacionáveis

2

Átomos Pesados

14

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A beta-lactam compound that acts as a suicide inhibitor of bacterial beta-lactamase enzymes by forming an irreversible covalent bond with the enzyme's active site. When combined with susceptible beta-lactam antibiotics such as amoxicillin, it dramatically expands antibacterial coverage to include many resistant organisms. It is not used as a standalone antibiotic due to its weak intrinsic antibacterial activity.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Clavulanic Acid is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL777. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5280980. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Clavulanic Acid no PillFYI

Estrutura

Dados Rápidos

Fórmula: C8H9NO5

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.